Novo Nordisk buckles down on lobbying efforts, inching toward CMS coverage of obesity treatments

No­vo Nordisk has spent the sum­mer build­ing out its lob­by­ing team on K Street as part of its ef­forts to get Medicare to cov­er obe­si­ty treat­ments.

No­vo in Ju­ly en­list­ed the Madi­son Group to fo­cus on Medicare cov­er­age of an­ti-obe­si­ty drugs, and specif­i­cal­ly Part D cov­er­age, ac­cord­ing to a re­cent­ly re­leased lob­by­ing reg­is­tra­tion form. The com­pa­ny, which man­u­fac­tures di­a­betes and obe­si­ty drugs We­govy and Ozem­pic, al­so hired Arnold & Porter in May and Sub­ject Mat­ter in June to work on this area.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.